individualized axitinib dosing for patients with metastatic renal cell carcinoma
Published 3 years ago • 206 plays • Length 3:30Download video MP4
Download video MP3
Similar videos
-
2:16
dr. rini on axitinib for treatment of metastatic renal cell carcinoma
-
9:52
phase 3 axitinib data in patients with previously treated advanced renal cell carcinoma
-
4:04
evaluation of brain metastases among renal cell carcinoma patients treated with avelumab & axitinib
-
4:30
neoadjuvant axitinib and avelumab for high-risk renal cell carcinoma
-
3:41
tide-a: avelumab and intermittent axitinib in metastatic renal cell carcinoma
-
8:31
second-line angiogenesis inhibition in metastatic renal cell carcinoma
-
3:26
extended follow-up from a trial of pembrolizumab plus axitinib for advanced renal cell carcinoma
-
3:30
promising results for axitinib and pembrolizumab in advanced renal cell cancer
-
1:00
pembrolizumab/axitinib and avelumab/axitinib combo for rcc
-
1:06
exciting potential of pembrolizumab combined with axitinib for kidney cancer
-
8:50
updated results of a clinical trial evaluating pembrolizumab axitinib for frontline adv rcc
-
1:31
naxiva: axitinib for reducing vtt in rcc
-
2:18
pembrolizumab monotherapy and pembro-axitinib for rcc
-
2:16
treating kidney cancer with axitinib &avelumab, or axitinib & pembrolizumab?
-
2:21
dr. voss on combining dalantercept and axitinib for advanced kidney cancer
-
11:26
axis trial: second-line axitinib versus sorafenib in metastatic renal cell carcinoma
-
4:35
atlas trial: axitinib in rcc- despite reporting no significant difference, some optimism remains
-
2:10
inlyta (axitinib)- advanced renal cell carcinoma (rcc)
-
4:39
avelumab and axitinib vs sunitinib in treating advanced renal cell carcinoma